ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1138

Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States

Timothy Edgil1, Kenneth Saag2, Jeffrey Curtis3 and Maria I. Danila2, 1Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2021

Keywords: Dual energy x-ray absorptiometry (DEXA), Health Services Research, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The twenty first century has seen falling reimbursement rates for dual energy X-ray absorptiometry (DXA) testing coupled with a rising elderly population in the U.S. The purpose of this study was to assess trends in performing DXA scans among U.S. medical providers and the resulting potential impact of reduced DXA availability on access to care.

Methods: A retrospective review was performed on publicly available data Medicare provider utilization and payment data between 2012 and 2018. Data was accessed from the CMS website and filtered for CPT codes used for reimbursement of DXA testing. This data included information on provider (name and identifier), city, state, zip code, sex, procedure type, location (office-based providers vs hospital-based providers), and provider specialty. Provider zip codes were compared to the Federal Office of Rural Health Policy (FORHP) designation as rural areas.

Results: From 2012-2018 the standardized number of DXA tests per 100,000 women decreased from 5,641 to 4,899 DXA tests per 100,000 women with a nadir of 4,307 DXA tests per 100,000 women in 2015. The number of DXA providers reimbursed located in a rural zip code decreased 41.3% (from 2,945 to 1,728), similar to the relative decrease in the proportion of rural providers (from 14.2% to 9.0%). The percentage of reimbursed DXA scans performed by rheumatologists decreased from 10.3% to 7.1%, internal medicine from 22.0% to 12.7%, obstetrics/gynecology from 6.5% to 4.2%, and family practice from 11.3% to 8.0%; diagnostic radiology, which are hospital-based providers, increased from 31.6% to 50.4% during the same time period.

Conclusion: The standardized number of DXA tests per 100,000 women Medicare enrollees decreased between 2012 and 2018. During the same time period, the claims for DXA testing for office-based specialties decreased, while the claims for DXA testing performed by diagnostic radiology increased. Both the number and proportion of both rural and primary care providers submitting claims for DXA testing have decreased, leading to likely decreased access to osteoporosis care among rural residents. With a progressive aging of the population, the access to tools for prevention and treatment of osteoporosis, such as DXA, is key to delivering high-quality osteoporosis care and effectively screening high risk patients.

Figure 1. Standardized Number of DXA Scans Per 100,000 Women by Year.

Figure 2. Yearly Trends in Percentages of DXA Testing by Specialty and Year.

Table 1. Standardized Yearly DXA Scans Per 100,000 Women by Specialty, 2012_2018. Columns sorted by: Total number of DXA scans in 2012; Number of DXA scans standardized per 100,000 women in 2012; Total number of DXA scans in 2018; Number of DXA scans standardized per 100,000 women in 2018.


Disclosures: T. Edgil, None; K. Saag, Arthrosi, 2, Atom Bioscience, 2, Horizon Therapeutics, 2, 5, LG Pharma, 2, Mallinkrodt, 2, SOBI, 2, 5, Takeda, 2, Shanton, 5; J. Curtis, AbbVie, 2, Amgen, 2, 5, Bristol-Myers Squibb, 2, Janssen, 2, Eli Lilly, 2, Myriad, 2, Pfizer Inc, 2, 5, Roche/Genentech, 2, UCB, 2, CorEvitas, 2, 5, Crescendo Bio, 5; M. Danila, Boehringer Ingelheim, 5, Amgen, 1, Amgen, 5, AbbVie, 1, Pfizer, 5, Pfizer, 11, Horizon, 5, Novartis, 1, WebMD, 12, writer.

To cite this abstract in AMA style:

Edgil T, Saag K, Curtis J, Danila M. Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/assessing-trends-in-dual-energy-x-ray-absorptiometry-dxa-utilization-among-medical-providers-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-trends-in-dual-energy-x-ray-absorptiometry-dxa-utilization-among-medical-providers-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology